Yoga Programs May Improve Quality of Life for Patients with NSCLC and Their Caregivers

Yoga Programs May Improve Quality of Life for Patients with NSCLC and Their Caregivers

This study evaluated the feasibility and potential efficacy of a yoga intervention for patients with NSCLC and their caregivers.

Language Barrier, Patient Ethnicity Do Not Delay Hospital Treatment in NSCLC

Language Barrier, Patient Ethnicity Do Not Delay Hospital Treatment in NSCLC

Impact of language barrier and patient ethnicity on time interval from diagnosis to treatment for patients with NSCLC was measured at a public hospital and a private hospital.

A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer

A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer

In this case, a female patient with advanced lung cancer experiences a rare episode of nivolumab-induced Herzmyasthenie, emphasizing the need to be aware of the potential for rapid myocarditis concomitant with MG in patients undergoing treatment with anti-PD-1 monoclonal antibodies.

Novel Predictive Model More Effectively Identifies Risk for Lung Cancer

Novel Predictive Model More Effectively Identifies Risk for Lung Cancer

PanCan study results demonstrate the effectiveness of a novel predictive model in identifying risk of lung cancer in patients who do not meet the screening criteria of other models, including those used in the NLST.

Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC

Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC

Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.

Osimertinib in the Treatment of Non-small Cell Lung Cancer: Design, Development and Place in Therapy

Osimertinib in the Treatment of Non-small Cell Lung Cancer: Design, Development and Place in Therapy

[Lung cancer: Targets and Therapy] This research examines clinical data from Phase I-III trials of osimertinib, discusses mechanisms of resistance to osimertinib, and provides an outlook for the use of osimertinib and novel therapeutic combinations to improve EGFR-mutated NSCLC outcomes.

Radiation Prior to Chemotherapy Prolongs Progression-Free Survival in NSCLC

Radiation Prior to Chemotherapy Prolongs Progression-Free Survival in NSCLC

Researchers present findings of a phase 2 study that compared PFS when SBRT is administered prior to maintenance chemotherapy in patients with limited metastatic NSCLC vs chemotherapy alone. Data was presented at ASTRO 59th Annual Meeting.

Spontaneous Tumor Lysis Syndrome in Recently Diagnosed Small Cell Lung Cancer

Spontaneous Tumor Lysis Syndrome in Recently Diagnosed Small Cell Lung Cancer

This case demonstrates that, although rare, spontaneous TLS can occur even in the absence of chemotherapy, and a high index of suspicion for the effect should be maintained when patients with malignancies demonstrate the classic symptom of laboratory abnormalities.

Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC

Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC

Patients with stage III NSCLC have a poor median PFS of 8 months despite achieving a good response to the current standard of care of platinum-based double chemotherapy with concurrent radiotherapy.

E-Cigarettes Increase BP, Heart Rate, Arterial Stiffness

E-Cigarettes Increase BP, Heart Rate, Arterial Stiffness

Significant increases seen in heart rate and arterial stiffness were observed in the first 30 minutes after smoking electronic-cigarette containing nicotine.

Eligibility Criteria a Barrier to Lung Cancer Clinical Trial Participation

Eligibility Criteria a Barrier to Lung Cancer Clinical Trial Participation

An investigation into the challenges of lung cancer clinical trials found that despite a lack of participants being detrimental to successful trial completion, clinical trials are trending toward increasing their eligibility criteria, making it more difficult to accrue enough eligible participants.

Vitamin B6 and B12 Supplements May Up Risk of Lung Cancer in Men

Vitamin B6 and B12 Supplements May Up Risk of Lung Cancer in Men

Vitamin B intake appears to be related to lung cancer risk, but only for men or male smokers.

Depth of Response Shows Potential as Clinical Outcome Measure in NSCLC

Depth of Response Shows Potential as Clinical Outcome Measure in NSCLC

A retrospective analysis showed an association between depth of response (DepOR) and greater overall survival and longer progression-free survival.

Psychosocial Challenges for Patients With Advanced Lung Cancer: Interventions to Improve Well-being

Psychosocial Challenges for Patients With Advanced Lung Cancer: Interventions to Improve Well-being

[Lung Cancer: Targets and Therapy] This research reviews the current literature on psychosocial interventions in lung cancer, and discusses .

Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin

Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin

Data from 5 phase 2/3 studies demonstrate improved weight and body mass in patients with NSCLC receiving anamorelin.

Undergoing CT Lung Cancer Screening May Motivate Quit Attempts in Persons at High Risk

Undergoing CT Lung Cancer Screening May Motivate Quit Attempts in Persons at High Risk

Contrary to some concerns, persons at high risk for lung cancer who undergo CT lung scans are more likely to attempt smoking cessation regardless of their test results compared with unscreened persons.

Risk of Lung Cancer Increases With Diets Higher in Saturated Fats

Risk of Lung Cancer Increases With Diets Higher in Saturated Fats

A recent study demonstrated that eating a diet high in saturated fats and low in polyunsaturated fats may increase a person's risk of developing lung cancer.

Survival Predictions for NSCLC Accurate With the Lung Cancer Prognostic Index

Survival Predictions for NSCLC Accurate With the Lung Cancer Prognostic Index

The Lung Cancer Prognostic Index (LCPI) provides additional relevant prognostic data for patients with NSCL and may lead to better outcomes.

Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics

Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics

An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.

Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes

Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes

E-cigarettes used with nicotine-based liquid have the same potential to produce cancer-causing DNA damage as unfiltered regular cigarettes.

Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC

Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC

Phase 3 clinical trial results show fewer adverse effects and longer survival with alectinib compared with crizotinib in patients with treatment-naïve ALK-positive NSCLC.

Improved Outcomes in Lung Cancer With Hyperfractionated Chemoradiation Therapy

Improved Outcomes in Lung Cancer With Hyperfractionated Chemoradiation Therapy

Twice daily radiation therapy with chemotherapy may improve survival times in patients with some advanced head and neck cancers, a new study confirms.

Filtered Cigarettes May Increase Rates of Lung Adenocarcinoma

Filtered Cigarettes May Increase Rates of Lung Adenocarcinoma

The design of cigarette filters with ventilation is associated with rising adenocarcinoma rates, research indicates.

No Improvement in KRAS-Mutation Lung Cancer With MEK Inhibitor Plus Chemotherapy

No Improvement in KRAS-Mutation Lung Cancer With MEK Inhibitor Plus Chemotherapy

A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.

Influenza Vaccination Increases Toxicity in PD-1/PD-L1 Immunotherapy Blockade for Lung Cancer

Influenza Vaccination Increases Toxicity in PD-1/PD-L1 Immunotherapy Blockade for Lung Cancer

Seasonal influenza vaccination was associated with increased rates of immunologic toxicity in patients with lung cancer receiving PD-1/PD-L1 immunotherapy blockade.

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.

Pembrolizumab May Help Combat Mesothelioma

Pembrolizumab May Help Combat Mesothelioma

Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.

Radiation Therapy for Locally Advanced NSCLC Linked to Cardiac Events

Radiation Therapy for Locally Advanced NSCLC Linked to Cardiac Events

Risk for cardiac events linked to RT for locally advanced NSCLC, especially in patients with a history of cardiac disease or receiving higher RT doses.

CTCs Promising as Biomarker to Identify Lung Cancer Recurrence

CTCs Promising as Biomarker to Identify Lung Cancer Recurrence

Prospective pilot study demonstrates accuracy of circulating tumor cells as a biomarker indicating lung cancer recurrence.

Free Lung Cancer Screening Findings Support Continual Screenings in High-Risk Populations

Free Lung Cancer Screening Findings Support Continual Screenings in High-Risk Populations

A free lung cancer screening program in Augusta, Georgia, found more than double the lung cancer rate of previous screenings.

Shared Decision-making Visits Improved Comfort With Lung Cancer Screening Decisions

Shared Decision-making Visits Improved Comfort With Lung Cancer Screening Decisions

Patients were more comfortable with their decisions about lung cancer screening after a shared decision-making visit.

Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer

Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer

Patients with metastatic kidney cancer may also have an primary lung cancer that has gone gone undiagnosed.

Nasal Biomarker in Smokers Could Predict Lung Cancer

Nasal Biomarker in Smokers Could Predict Lung Cancer

Novel diagnostic test determines whether suspicious lung lesions or nodules are malignant disease from a sample obtained via nasal swab.

Proportion of Never-Smokers With NSCLC Is on the Rise

Proportion of Never-Smokers With NSCLC Is on the Rise

A study of a large, diverse patient population appears to show an increasing incidence of lung cancer in patients who have never smoked tobacco.

Patients with Lung Cancer Do Not Benefit from Statins

Patients with Lung Cancer Do Not Benefit from Statins

Statins provide no benefits, or adverse effects, in patients with lung cancer, according to a phase 3 trial.

NSCLC: Pathway Navigation Program Lowers Costs of Care

NSCLC: Pathway Navigation Program Lowers Costs of Care

A clinical pathways navigation program for patients with non-small cell lung cancer significantly reduced cost of care while preserving clinical outcomes.

FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC

FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC

Ceritinib has been granted Priority Review as a first-line treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.

E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use

E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use

E-cigarettes and replacement nicotine therapy deposit fewer harmful chemicals in the body that smoking.

Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments

Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments

Elderly with NSCLC have lower incidence of esophagitis, can tolerate aggressive radiation therapy.

Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods

Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods

Annual lung cancer screening of only high-risk smokers more cost-effective than current methods.

Lung Cancer Screening Rates Low Among Present and Former Smokers

Lung Cancer Screening Rates Low Among Present and Former Smokers

Researchers estimate that out of the 6.8 million current and former smokers eligible for lung cancer screening in 2015, only a fraction received it.

New Study Shows Standard of Care for NSCLC Patients Leads to Improved Overall Survival

New Study Shows Standard of Care for NSCLC Patients Leads to Improved Overall Survival

There are a growing number of NSCLC patients with advanced disease who are opting to forgo treatment despite the fact that receiving standard of care treatment leads to a higher OS.

Nut Consumption Inversely Associated With Lung Cancer Risk

Nut Consumption Inversely Associated With Lung Cancer Risk

A higher consumption of nuts was associated with a lower overall risk for developing lung cancer irrespective of smoking status.

Many VHA Patients Eligible for Lung Cancer Screening

Many VHA Patients Eligible for Lung Cancer Screening

Second study shows increase in lung cancer screening from 1.3 to 2.1 percent from 2010 to 2015

Addition of Bevacizumab to Chemo Improves PFS in Extensive SCLC

Addition of Bevacizumab to Chemo Improves PFS in Extensive SCLC

The addition of bevacizumab to first-line treatment with cisplatin plus etoposide improved PFS, but not OS, with an acceptable toxicity profile in patients with extensive-disease SCLC.

Use of Upfront TKIs Linked to Inferior OS in EGFR+ NSCLC With Brain Metastases

Use of Upfront TKIs Linked to Inferior OS in EGFR+ NSCLC With Brain Metastases

Treatment options for brain metastases in patients with EGFR-mutant NSCLC include SRS, WBRT, and EGFR TKIs. In this study, researchers sought to determine the optimal treatment approach of those who develop brain metastases and have not received EFGR TKIs.

First-line Ceritinib Improves PFS vs Chemo in Advanced ALK-rearranged NSCLC

First-line Ceritinib Improves PFS vs Chemo in Advanced ALK-rearranged NSCLC

Ceritinib is a kinase inhibitor indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib; in this study, researchers determined the efficacy of ceritinib in patients with untreated ALK-rearranged NSCLC.

Many Advanced NSCLC Patients Not Getting Helpful Treatment

Many Advanced NSCLC Patients Not Getting Helpful Treatment

Study found 21 percent of those with late-stage non-small cell lung cancer went without therapy, even though it could boost survival.

Tobacco Counseling for Youth, Adults Reduces Smoking Prevalence

Tobacco Counseling for Youth, Adults Reduces Smoking Prevalence

Annual counseling could reduce prevalence and prevent many smoking-attributable fatalities.

No Differences in Lung Cancer Mutations Between White, Black Patients

No Differences in Lung Cancer Mutations Between White, Black Patients

Analyses of lung tumor specimens were used to determine whether mutational profiles of lung cancers differ between black and white patients. Such differences could explain differences in prognosis and lead to reductions in outcomes disparities.

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

Investigators report on trends in treatment of advanced-stage NSCLC from 2000 to 2011, including impact on survival and total Medicare spending.

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.

Comparison of Three Information Sources for Smoking Information in Electronic Health Records

Comparison of Three Information Sources for Smoking Information in Electronic Health Records

[Cancer Informatics] This research examinbed independent and joint performance of retrieving smoking status through different sources and compared the performance of retrieving smoking strength information from narrative text and PPI.

The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma

The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma

[OncoTargets and Therapy] The surgical approach that offers the best outcomes for malignant pleural mesothelioma management is still debated. This research examines the efficacy of surgical treatment.

Cisplatin-etoposide and Carboplatin-paclitaxel With RT Comparable for Stage III Lung Cancer

Cisplatin-etoposide and Carboplatin-paclitaxel With RT Comparable for Stage III Lung Cancer

Carboplatin-paclitaxel with concurrent RT has comparable efficacy with cisplatin-etoposide plus RT in patients with stage III NSCLC.

Atezolizumab Prolongs Survival vs Docetaxel in Previously Treated NSCLC

Atezolizumab Prolongs Survival vs Docetaxel in Previously Treated NSCLC

The efficacy and safety of atezolizumab in patients with previously treated NSCLC was evaluated in the OAK trial, an open-label, pivotal, phase 3 study, the results of which were recently published.

Survival Not Better With Onartuzumab Plus Erlotinib for MET-Positive NSCLC

Survival Not Better With Onartuzumab Plus Erlotinib for MET-Positive NSCLC

Results of the METLung trial are presented. In this trial, researchers evaluated the efficacy and safety of onartuzumab in patients with advanced NSCLC selected by MET immunohistochemistry.

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

A study presented at the World Conference on Lung Cancer compared progression-free survival after treatment with osimertinib with that of platinum therapy plus pemetrexed in a select group of patients with T790M-positive advanced NSCLC.

Mental Health Disorder Linked to Poorer Survival in NSCLC

Mental Health Disorder Linked to Poorer Survival in NSCLC

Among patients with non-small cell lung cancer (NSCLC), those with a mental health disorder appeared to have a higher risk of death.

Intermittent Hypoxia Promotes Lung Tumor Cell Aggressiveness

Intermittent Hypoxia Promotes Lung Tumor Cell Aggressiveness

IH-induced exosomes from mice significantly promote TC1 malignant properties, according to a recent study.

Vandetanib Potentially Efficacious in RET-Rearranged NSCLC

Vandetanib Potentially Efficacious in RET-Rearranged NSCLC

In a multicenter, open-label, phase 2 study, researchers evaluated the activity and safety of vandetanib in patients with advanced RET-rearranged NSCLC.

Vandetanib Moderately Active in RET+ Advanced NSCLC

Vandetanib Moderately Active in RET+ Advanced NSCLC

Researchers report on their evaluation of the efficacy and safety of vandetanib, a kinase inhibitor of VEGFR, EGFR, and the RET-tyrosine kinase, in patients with NSCLC tumors with chromosomal rearrangements involving RET.

HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC

HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC

This study focused on determining the effectiveness of a short-term high-intensity interval training (HIIT) program to improve patients' cardiorespiratory fitness prior to NSCLC resection.

Smoking-related Cancer Deaths Highest in Southern United States

Smoking-related Cancer Deaths Highest in Southern United States

Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.

Atezolizumab Granted FDA Approval for Specific Cases of NSCLC

Atezolizumab Granted FDA Approval for Specific Cases of NSCLC

Atezolizumab (Tecentriq) is approved by the FDA for the treatment of metastatic NSCLC in specific cases or tumors with EGFR or ALK gene mutations.

First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

The addition of pembrolizumab to carboplatin and pemetrexed improves overall response rate compared with chemotherapy alone and has a manageable safety profile in patients with newly diagnosed advanced nonsquamous NSCLC.

Lenvatinib Shows Promising Activity in RET+ NSCLC

Lenvatinib Shows Promising Activity in RET+ NSCLC

Treatment with the kinase inhibitor lenvatinib demonstrated promising activity in patients with RET-positive NSCLC.

Depression Linked to Increased Mortality in Lung Cancer

Depression Linked to Increased Mortality in Lung Cancer

Changes in depression symptoms over time are associated with differences in survival among patients with lung cancer, especially those with early stage disease.

Decision Aids Help Patients Understand Lung Cancer Screening

Decision Aids Help Patients Understand Lung Cancer Screening

Patient understanding of lung cancer screening increased after participation in focus groups.

Study Supports Routine Use of IMRT for Locally Advanced NSCLC

Study Supports Routine Use of IMRT for Locally Advanced NSCLC

IMRT was associated with lower rates of severe pneumonitis and cardiac doses compared with 3D-CRT in patients with locally advanced NSCLC.

Analysis of Population Trends Shows Use of Electronic Cigarettes Increase Quit Success

Analysis of Population Trends Shows Use of Electronic Cigarettes Increase Quit Success

An analysis of population trends in England demonstrated that use of electronic cigarettes improves the rate of successful quit attempts, but results in less use of prescription nicotine-replacement therapy products.

WBRT Adds Little Benefit for NSCLC With Brain Metastases

WBRT Adds Little Benefit for NSCLC With Brain Metastases

Adding WBRT to dexamethasone and best supportive care provides little additional benefit for patients with NSCLC and brain metastases who are ineligible to undergo resection or stereotactic radiotherapy.

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage SCLC.

Combination Therapy With Hypoxia-Activated Prodrug Prevents Drug Resistance in NSCLC Subtype

Combination Therapy With Hypoxia-Activated Prodrug Prevents Drug Resistance in NSCLC Subtype

Hypoxia-activated prodrugs prevented treatment resistance in a mathematical model of EGFR mutation-driven non-small cell lung cancer (NSCLC).

TKIs Improve Overall Survival in NSCLC Patients With Leptomeningeal Metastases

TKIs Improve Overall Survival in NSCLC Patients With Leptomeningeal Metastases

Longer overall survival was achieved with TKIs targeting EGFR mutations in non-small cell lung cancer (NSCLC) patients.

In NSCLC, Erlotinib Appears Effective at Doses Lower Than MTD

In NSCLC, Erlotinib Appears Effective at Doses Lower Than MTD

Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.

Hybrid Immune Cells Have Antitumor Effects in Early Stage Lung Cancer

Hybrid Immune Cells Have Antitumor Effects in Early Stage Lung Cancer

A subset of tumor-associated neutrophils (TANs) has hybrid characteristics of both neutrophils and antigen-presenting cells in samples from early stage human lung cancers.

Web Application Improves Follow-up in Patients With Advanced Lung Cancer

Web Application Improves Follow-up in Patients With Advanced Lung Cancer

A Web application called Moovcare that guides follow-up improved survival for patients with advanced lung cancer after receiving initial therapy.

Annual Follow-up With Low-Dose CT Is Sufficient for Some Lung Nodules

Annual Follow-up With Low-Dose CT Is Sufficient for Some Lung Nodules

For nonsolid nodules identified by CT screening for lung cancer, annual screening with low-dose CT can eliminate the need for biopsy or surgery.

Nonsolid Nodules Unlikely to Cause Death in Lung Cancer

Nonsolid Nodules Unlikely to Cause Death in Lung Cancer

Lung cancers that manifest as nonsolid nodules seem to have indolent course, according to recent research data.

Surgery Improves Quality of Life for Patients With Malignant Pleural Mesothelioma

Surgery Improves Quality of Life for Patients With Malignant Pleural Mesothelioma

Undergoing pleurectomy and decortication for malignant pleural mesothelioma generally leads to improved quality of life after the surgery.

Lung Cancer Signature Detected Via Breath Test Improves Early Diagnosis

Lung Cancer Signature Detected Via Breath Test Improves Early Diagnosis

Breath analysis offers an option for both primary screening and postsurgery monitoring of patients with lung cancer. Exhaled breath has certain carbonyl VOCs that indicate the presence of lung cancer in a process researchers hope will receive FDA approval.

Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer

Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer

Results from phase II trial on the use of FDG-PET to evaluate the efficacy of an immunotherapy drug in the treatment of NSCLC.

Up to One-Quarter of Patients With Lung Cancer Ineligible for Immunotherapy

Fourteen percent to 25% of patients with lung cancer also have autoimmune disease. This comorbidity could make them unsuitable candidates for immunotherapy.

Adjuvant Chemotherapy Improves Overall Survival in Early Stage NSCLC

Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.

Adjuvant Chemotherapy Improves Survival in Stage IB NSCLC

Adjuvant Chemotherapy Improves Survival in Stage IB NSCLC

In patients with completely resected stage IB NSCLC, adjuvant chemotherapy is associated with improved survival regardless of tumor size.

More Survivors of AYA Cancer Smoke Than Those Without Cancer

More Survivors of AYA Cancer Smoke Than Those Without Cancer

Cigarette smoking is more common among survivors of AYA cancer than those without cancer, and smoking is associated with greater comorbidities and poorer general health.

Biochemical Marker Is a Better Predictor of Adverse Effects in Patients with Non-small Cell Lung Cancer

Albumin concentration with an established cutoff point is proven a better predictor of both chemotherapy toxicity and survival in patients with advanced lung cancer.

Referrals for Lung Cancer CT Imaging Screening Remain Low Among Family Physicians

Most family physicians report discussing low-dose CT imaging with patients at high risk for lung cancer, but referrals for screening remain low, a study published in the journal Cancer has shown.

CDC: Cigarette Smoking Drops in U.S. Adolescents

CDC: Cigarette Smoking Drops in U.S. Adolescents

A decreasing number of adolescents are smoking, but e-cigarette use and rates of distracted driving are on the rise for this group.

Modern Management of Malignant Pleural Mesothelioma

Modern Management of Malignant Pleural Mesothelioma

[Lung Cancer: Targets and Therapy] This research evaluates the addition of bevacizumab to standard chemotherapy as well as with the use of immune checkpoint inhibitors in malignant pleural mesothelioma (MPM).

Consensus Statement Guides Optimal Management of EGFR-Mutation-Positive NSCLC

Consensus Statement Guides Optimal Management of EGFR-Mutation-Positive NSCLC

The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage EGFR-mutation-positive NSCLC.

Optimal Delivery of Follow-up Care Following Pulmonary Lobectomy for Lung Cancer

Optimal Delivery of Follow-up Care Following Pulmonary Lobectomy for Lung Cancer

[Lung Cancer: Targets and Therapy] In this research, a literature review identifies international guidelines associated with non-small-cell lung cancer (NSCLC) recurrence useful as remedies in postoperative follow-up.

Including Quality Measures In Treatment Regimens Increases Survival in Stage IIIA Non-Small Cell Lung Cancer

Including Quality Measures In Treatment Regimens Increases Survival in Stage IIIA Non-Small Cell Lung Cancer

When more quality measures are incorporated into patient care, survival rates for patients with stage IIIA non-small cell lung cancer (NSCLC) increase, but only 13% of eligible patients actually receive all 4 recommended quality measures.

Older Patients With Lung Cancer Experience High Survival After Surgery

Older Patients With Lung Cancer Experience High Survival After Surgery

Results from this study showed that 5-year survival for older patients after surgery for lung cancer is favorable. Based on these results, surgeons might be better equipped to individualize care for this older population.

Increased Risk of Noncancer Deaths Associated with Stereotactic Body Radiation Therapy for Lung Cancer

High doses of SBRT, particularly to the left atrium of the heart and the superior vena cava, are associated with a small but increased risk of death from noncancer causes in patients with early stage NSCLC.

VATS Associated With Less Post-op Pain, Better QoL for Stage 1 NSCLC

VATS Associated With Less Post-op Pain, Better QoL for Stage 1 NSCLC

Video-assisted thoracoscopic surgery (VATS) is associated with less postoperative pain and better quality of life than anterolateral thoracotomy for the first year of surgery in patients with stage I NSCLC.

Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer

Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer

[Cancer Management and Research] This research examines the use of proactive GI AE management strategies for patients with non-small-cell lung cancer being treated with ceritinib.

Necitumumab With Chemotherapy Beneficial for Patients With EGFR-expressing NSCLC

Necitumumab With Chemotherapy Beneficial for Patients With EGFR-expressing NSCLC

The most benefit from adding necitumumab to chemotherapy with gemcitabine and cisplatin occurred for patients whose advanced squamous NSCLC expressed EGFR.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs